SpringWorks raises $125M series B round
A year and a half after raising its initial round of funding to develop programs spun out of Pfizer, SpringWorks has raised $125 million in a series B round. The company now has funding to complete pivotal studies of its two most advanced oncology programs, and aims to start both this half.
Perceptive Advisors led the new round for SpringWorks Therapeutics Inc. (Stamford, Conn.)...
BCIQ Company Profiles